

GAVI'S ROLE IN SUPPORT TO REGIONAL AND AFRICAN VACCINE MANUFACTURING

BOARD MEETING

Dominic Hein, David Kinder

7-8 December 2022, Geneva, Switzerland

The African region, while having significant demand for vaccines, currently has limited regional manufacturing




Figure: Supply of WHO pre-qualified vaccines in 2021
Source: WHO, Linksbridge

- Limited regional manufacturing, particularly in Africa, may have contributed to delays in equitable vaccine access during C-19 pandemic
- This highlighted that supply security is not always guaranteed
- Desire from many African countries to increase local capacity – for both pandemic response and routine / interpandemic vaccines
- Broad support from international community
- Gavi has opportunity to support given market shaping experience & large volumes procured
- Gavi's contribution will have a downstream focus that synergises with actors upstream

A four Pillar “downstream” approach for Gavi to provide support to regional manufacturing – with a focus on Africa

1

Support **shaping of regional product portfolios** to ensure targeting of vaccines most contributory to global market health

2

Adapt Gavi’s **Healthy Market Framework & Product Menu Criteria** to facilitate listing / adoption of geographically diverse products

3

Provide investors in new manufacturing capacity with **more predictability around eventual demand**


4

A **new financial instrument** to bridge cost gaps and incentivise manufacturers and investors in Africa

4

Advance Market Commitment to support the sustainable expansion of end-to-end African vaccine manufacturing

30+ vaccine manufacturing announcements in 14 countries



PHASE 1 – Ongoing to December 2022

- Consulted on concept, with emerging consensus upon priorities & scope

Objectives

1. Support healthy global markets
2. Drive efficient market outcomes
3. Reduce barriers to investment

Additional priorities identified

Targeted at African manufacturers

Preserve competitive market structure by awarding incentives in post-tender process

Time-limited financial support

AMC would require additional funding

PHASE 2 – beginning in early 2023 (subject to Board)

- In-depth multi-stakeholder process to agree upon detailed instrument design.

Recommendation

The Gavi Alliance Programme and Policy Committee **recommends** to the Gavi Alliance Board that it:

Approve the first three pillars of the new approach, namely 1) support for antigen and product portfolio planning; 2) adaptation of the Healthy Market Framework and Product Menu Criteria to facilitate listing and adoption of new regional products; and 3) providing investors in new manufacturing capacity with more predictability around eventual demand.

Noting information provided in Annex C following guidance from the Gavi Alliance Programme and Policy Committee, it is **recommended** that the Gavi Alliance Board:

Request that the Secretariat work up detailed proposals for the design and operationalisation of Pillar 4: an Advance Market Commitment to accelerate the expansion of end-to-end African vaccine manufacturing, with three underlying objectives: (i) support healthy global markets, (ii) drive efficient market outcomes, (iii) reduce barriers to investment, noting that detailed parameters will return to the Gavi Alliance Board for consideration and approval in 2023.